Table 2

Treatments and outcomes according to tobacco use status

Non-tobacco usersEx-tobacco usersCurrent tobacco usersp Value
N (%)3742 (47%)1363 (17%)2834 (36%)
Inhospital therapy
 Glycoprotein IIb/III-a inhibitor219 (5.9%)* 96 (7.1%)210 (7.4%)0.03
 Thrombolytic therapy 584 (48.3%) 251 (42.6%) 835 (55.4%)0.001
 Aspirin3672 (98.2%)1336 (98.2%)2793 (98.7%)0.20
 Clopidogrel2474 (66.2%) 1129 (83%) 2438 (86.1%)0.001
 ACE inhibitor2583 (69.1%) 1004 (73.8%)2017 (71.2%)0.004
 Angiotensin receptor blocker240 (6.4%) * 73 (5.4%) * 81 (2.9%)0.001
 β-Blockers2782 (74.4%)995 (73.1%)2118 (74.8%)0.5
 Statins3487 (93.3%) 1297 (95.3%)2730 (96.5%)0.001
 Calcium channel blockers370 (9.9%)* 87 (6.4%)* 119 (4.2%)0.001
Discharge medications
 Aspirin3443 (92.2%) 1255 (92.2%) 2659 (94.0%)0.01
 Clopidogrel2116 (56.6%) 1036 (76.4%) 2211 (78.1%)0.001
 β-Blockers2916 (78.2%) 1062 (78.3%) 2290 (81%)0.01
 ACE inhibitor2558 (68.6%) 994 (73.3%)2089 (73.9%)0.001
 Angiotensin receptor blocker302 (8.1%)* 108 (8%)* 126 (4.5%)0.001
 Statin3335 (89.5%) 1241 (91.5%) 2641 (93.5%)0.001
 Calcium channel blockers397 (10.6%)* 81 (6%)* 140 (5.0%)0.001
Inhospital complications
 Recurrent ischaemia563 (15.0%)267 (19.6%)* 403 (14.2%)0.001
 Recurrent myocardial infarction77 (2.1%)* 54 (4.0%)* 41 (1.4%)0.001
 Ventilation187 (5.0%)* 75 (5.5%)* 108 (3.8%)0.02
 Heart failure520 (13.9%)* 213 (15.7%)* 308 (10.9%)0.001
 Cardiogenic shock212 (5.7%)96 (7.1%)* 150 (5.3%)0.01
 Major bleeding25 (0.7%)10 (0.7%)13 (0.4%)0.4
 Stroke27 (0.7%)12 (0.9%)17 (0.6%)0.6
 Death206 (5.5%)* 63 (4.6%)* 93 (3.3%)0.001
 1-Month death307 (9.3%)* 107 (8.8%)* 159 (6.4%)0.001
 1-Year death429 (15%)* 135 (12.4%)* 208 (9.5%)0.001
  • * p≤0.05 (indicates increase in comparison with current tobacco users).

  • p<0.05 (indicates decrease in comparison with current tobacco users).

  • PCI of those eligible for reperfusion therapy.

  • PCI, percutaneous coronary intervention.